Neoadjuvant chemoradiotherapy followed by esophagectomy versus definitive chemoradiotherapy in resectable stage II/III (T1-3N0, 1M0) esophageal squamous cell carcinoma

Content Provider	Semantic Scholar
Author	Nagata, Matsuo Yamamoto, Hiroshi Takiguchi, N. Kainuma, Osamu Cho, Akihiro Mori, Mikito Narumoto, Sohichi Asano, Takehide Hatano, Kazuo
Copyright Year	2006
Abstract	BackgroundThere are two intensive modalities for the treatment of resectable esophageal carcinoma: esophagectomy and definitive chemoradiotherapy (CRT). Esophagectomy with preoperative CRT was retrospectively compared with CRT alone in resectable stage II/III esophageal squamous cell carcinoma.MethodsSeventy-four patients with resectable stage II/III (T1-3N0, 1M0) esophageal squamous cell carcinoma were treated with preoperative CRT by 5-fluorouracil (5-FU) 700 mg/m2 on days 1 to 5, nedaplatin 80 mg/m2 on day 1, and concurrent radiation for a total of 30 Gy in 3 weeks. If patients decided to undergo surgery, esophagectomy from the thoracoabdominal approach was carried out 6 weeks after the completion of CRT (CRT + Surg group, n = 51). If patients decided not to undergo surgery, they were treated with one more course of CRT (CRT-alone group, n = 23).ResultsThere was no significant difference in overall survival between the two groups (P = 0.1006), whereas the disease-free survival in the CRT + Surg group was improved compared with the CRT-alone group (P = 0.0186). In the patients with clinical stage III carcinoma or with regional lymph node metastasis, the overall survival rate was significantly improved in the CRT + Surg group compared with the CRT-alone group. The rate of local failures in the CRT + Surg group was significantly lower compared with the CRT-alone group (P = 0.0011).ConclusionsPreoperative CRT followed by esophagectomy provides better local control, but does not prolong overall survival, compared with definitive CRT. However, in clinical stage III or N1, esophagectomy with preoperative CRT could contribute to the improvement of survival in esophageal squamous cell carcinoma.
Starting Page	105
Ending Page	111
Page Count	7
File Format	PDF HTM / HTML
DOI	10.1007/s10388-006-0081-9
Alternate Webpage(s)	https://page-one.live.cf.public.springer.com/pdf/preview/10.1007/s10388-006-0081-9
Alternate Webpage(s)	https://doi.org/10.1007/s10388-006-0081-9
Volume Number	3
Journal	Esophagus
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article